Publications by authors named "J A Rottingen"
The pipeline of new antibiotics is insufficient to keep pace with the growing global burden of drug-resistant infections. Substantial economic challenges discourage private investment in antibiotic research and development (R&D), with a decline in the number of companies and researchers working in the field. Compounding these issues, many countries (from low income to high income) face a growing crisis of antibiotic shortages and inequitable access to existing and emerging treatments.
View Article and Find Full Text PDFArticle Synopsis
- - Rising antimicrobial resistance (AMR) threatens global health and undermines development goals like child survival, poverty reduction, and food security, necessitating a coordinated response to preserve antibiotic effectiveness.
- - The upcoming UN General Assembly meeting in September 2024 highlights a political commitment to address AMR, but meaningful action is essential, including setting clear targets for reduction in AMR-related mortality and inappropriate antibiotic use by 2030.
- - To manage antibiotic use properly, a framework utilizing the WHO's AWARE system is recommended, alongside improved infection prevention measures, access to clean water, and vaccinations, while establishing an independent panel to ensure accountability and guidance across countries.
To ensure optimal coordination of the EU-funded COVID-19 platform trials, a double coordination mechanism was established. It included the Trial Coordination Board (TCB) to promote the dialogue between investigators and relevant public health stakeholders and the Joint Access Advisory Mechanism (JAAM) to streamline access of new intervention arms to the platform trials. Both the TCB and the JAAM emerged as efficient instruments to promote cooperation and optimise the use of resources within EU-funded adaptive platform trials.
View Article and Find Full Text PDF